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duration of surgical prophylaxis for clean cases. This inap-
propriate antibiotic usage increases the selective pressure
favoring the emergence of antimicrobial resistance and colo-
nization of drug resistant strains. Judicious use of antibiotics
is thus essential.
Methods: A prospective study was carried out in 2 surgical
units in Wockhardt hospital, Bangalore, India to evaluate the
prescription pattern of antibiotic prophylaxis and to deter-
mine the impact of prolonged antibiotic usage. Standardized
recommendations were developed for prophylactic antibi-
otic usage. Cardiac and orthopedic cases undergoing clean
surgical procedures were included in the study. By review-
ing the infection monitoring worksheets the incidence of
healthcare associated infections were detected
Results: A total of 120 cases, 60 of each unit were evalu-
ated. It was noticed that although all cases received a single
pre-operative prophylactic injectable antibiotic, it was not
consistent as to the timing of the dose and the repetition
of another dose intra-operatively if required. For orthope-
dic cases antibiotic was continued for 24 hours and more
than 72 hours for cardiac cases. Antibiotic chosen for car-
diac cases were either a third generation cephalosporin or
a combination of third generation cephalosporin with a 
lactamase inhibitor and for orthopedic cases only a second
generation cephalosporin was used. The impact of prolonged
antibiotic usage was monitored by the rate of healthcare
associated infection. The rate for cardiac cases was 5% and
there were no infections for orthopedic cases.
Conclusion: There is need for change from these con-
ventional practices of prolonged ‘‘prophylactic’’ antibiotic
usage to prevent post operative infections in clean cases.
doi:10.1016/j.ijid.2008.05.1089
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Synthesis and Antibacterial Activity of Piperazinyl Oxazo-
lidinones Containing 5-(4-methyl-1,2,3-triazole)
O.A. Phillips ∗, E.E. Udo, M. Abdel-Hamid, R. Verghese
Kuwait University, Safat, Kuwait
Introduction: The bioisosteric replacement of the 5-
acetamidomethyl group of linezolid by 5-triazolylmethyl
yielded compounds with superior antibacterial activity
against Gram-positive bacteria strains. Replacing mor-
pholine by acylpiperazinyl yielded compounds including
PH038-PH047 with improved activities compared with PH-
027 and linezolid. Furthermore, methyl substitution at
4-position of the triazole exhibited reduced monoamine
oxidases and mitochondrial protein synthesis inhibition,
while retaining good antibacterial potency. In this study we
investigated the antibacterial activity of novel 5-(4-methyl-
1,2,3-triazolyl)methyl oxazolidinones (PH-series) bearing
morpholine and acylpiperazinyl moieties.
Methods: Novel 5-(4-methyl-1,2,3-triazole)methyl oxa-
zolidinones were synthesized and evaluated against Gram-
positive clinical isolates in comparison to linezolid, van-
comycin and PH-027. Organisms tested included methicillin-
susceptible (MSSA, n = 10) and -resistant S. aureus (MRSA,
n = 10); methicillin-susceptible (MS-CNS, n = 6) and -resistant
coagulase-negative staphylococci (MR-CNS, n = 3); and
vancomycin-susceptible (VSE, n = 6) and -resistant entero-
cocci (VRE, n = 4) and standard reference strains (n = 3).
Minimum inhibitory concentrations (MIC’s, ug/ml) were
determined by agar dilution method on Mueller Hinton agar
with the medium containing dilutions of antibacterial agents
ranging from 0.12—64 ug/ml, with and without 50% human
plasma
Results: The most active compound, isopropylcar-
bonylpiperazino derivative (PH-121, ClogP: -0.097) with MIC
range 0.5—1ug/ml showed comparable activity to line-
zolid and PH-27 (MIC, 0.5—1 ug/ml) against all strains.
This was followed by the morpholino (PH-84, Clog P:
0.900) and dichloroacetylpiperazino (PH-119, Clog P: 1.494)
derivatives with MIC ranges of 0.5—2 ug/ml, respectively.
Substitution with bulky acyl groups at the distal piper-
azine 4-position gave PH-108 (R = tert-butoxycarbonyl),
PH-128 (R = heptanoyl) and PH-131 (R = trans-cinnamoyl)
with reduced antibacterial activity and MIC ranges of 2—8,
4—8 and 8—16 ug/ml, respectively. Most of the new com-
pounds showed increased MIC values in the presence of 50%
human plasma suggesting plasma instability or binding.
Conclusion: All the compounds tested exhibited moder-
ate to strong antibacterial activity against all Gram-positive
cocci evaluated. The study highlighted signiﬁcant structure-
antibacterial activity relationships. Project is funded by the
Research Administration, Kuwait University, Grant numbers
PC01/05 (OAP) and GS01/01 and GS03/01 [Science Analyti-
cal Facilities (SAF)].
doi:10.1016/j.ijid.2008.05.1090
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Background of the study: Enteric fever caused by
Salmonella is the most common febrile illness in Nepal and
increasing/changing trend of antimicrobial resistance (AMR)
in Salmonella species has constituted a serious threat to
the public health. Methods used: This study was conducted
at 10 major hospitals/laboratories of Nepal during 2006
under AMR surveillance program. Standard microbiological
methods including serotyping were used for identiﬁcation.
Resistance screening was also carried out by standard Kirby-
Bauer disk-diffusion method
Results: Of the total 1611 Salmonella strains isolated
in 2006, 1147 isolates (63.7%), 448 isolates (24.9%) and
16 isolates (0.9%) were conﬁrmed to be Salmonella typhi,
S. paratyphi A and other Salmonella species respectively.
Salmonella typhi isolates showed 100% susceptibility to Cef-
triaxone and Oﬂoxacin, but high (67%) resistance to Nalidixic
acid followed by 3% resistance to Ampicillin. For S. paraty-
phi A, 100% susceptibility was observed with Tetracycline
only and the resistance rate was higher (89% resistance to
Nalidixic acid, 10% to Ampicillin and 3% to Oﬂoxacin) than
that observed with S. typhi. Similar resistance trend for
both serotypes was found towards Chloramphenicol, Cotri-
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moxazole and Ciproﬂoxacin. AMR surveillance revealed that
the prevalence of multi-drug resistant (MDR) Salmonella
(resistant to three or more at a time) has been decreas-
ing gradually (30% in 2002, 13%in 2003, 5% in 2004 and 2%
each in 2005 and 2006) in Nepal.
Conclusions: Although the number of MDR Salmonella has
been decreasing in Nepal, the total number of Salmonella
isolates has been increasing. The increasing trend of S.
paratyphi A with high resistance rate of Nalidixic acid can be
regarded as a worrisome situation and may reﬂect the emer-
gence of ﬂuoroquinolone resistance. Continued surveillance
and inclusion of appropriate antimicrobials in the routine
susceptibility testing for Salmonella are necessary in Nepal.
doi:10.1016/j.ijid.2008.05.1091
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pital of ShenZhen, ShenZhen, China
Background: The hepatitis B virus (HBV) is an enveloped
DNA virus with an icosahedral capsid replicating via reverse
transcription. The crystal structure of the capsid is known.
The viral envelope contains three different coterminal pro-
teins (S, M, and L proteins) spanning the membrane several
times. Hepatitis B virus large surface protein ‘LHBs’ has
the unusual property of accumulating in a particulate form
within a preGolgi compartment, leading to marked prolifer-
ation of intracellular membranes
Objective: The aim of this study was to investigate the
clinical value of LHBs used for diagnosis of the clinical hep-
atitis B patient and relativity with replication of hepatitis B
virus.
Methods: A total of 600 HBsAg positive patients in
The Fourth people’s hospital of Shenzhen between April-
December 2006 were included to the study. The patients
were classiﬁed into two groups according to their serologi-
cal patterns (Group 1: HBeAg positive 300 cases; Group 2:
HBeAg negative 300 cases). The age and gender distribu-
tions of the groups were similar. HBV serological markers and
LHBs have been detected by Enzyme Linked Immunosorbent
Assay (ELISA), and viral load (HBV-DNA) were investigated
by real-time polymerase chain reaction(PCR)
Results: No signiﬁcant difference of positive rate was
observed between HBV DNA 76.17% (457/600) and LHBs
77.33% (464/600) (X2 = 0.696, P > 0.05) in 600 HBsAg-positive
serum samples; Postive rate of HBV DNA and LHBs were 95.0
(285/300) and 96.0 (288/300) in HBeAg postive samples and
were 57.33 (172/300) and 58.67 (176/300) in HBeAg neg-
ative samples(X20.725, P > 0.05; X20.253, P > 0.05); Serum
LHBs levels were correlated with the serum HBV DNA copies
(r = 0.948).
Conclusion: The results demonstrated that there is a per-
fect correlation between the copies of HBV-DNA and the
levels of LHBs, and LHBs expression can reﬂect the repli-
cation of HBV.
doi:10.1016/j.ijid.2008.05.1092
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Objective: The persistence of Anti-HBc IgM among inac-
tive HBsAg carriers may be with hidden dangers anf forecasts
the existence of liver damage. A trial of lamivudine in such
carriers was carried out for the ﬁrst time in this study.
Patients and Methods: A total of 62 Inactive HBsAg carri-
ers (age range; 25—45 years) with persistence of anti-HBc
IgM were randomized to receive either 100mg lamivu-
dine (32/62) or placebo (30/60) daily for 6 months. The
studied carriers were regular attendees of the Virology
Center in Mosul, North Iraq for follow-up. Enzyme-linked
immunosorbent assay techniques were performed to detect
the different markers of HBV infection
Results: Among the lamivudine group, anti-HBc IgM serol-
clearance rate was 81.3% and HBsAg seroconversion rate was
9.4% compared to 6.3% and 3.3% among placebo group. Num-
ber of adverse clinical events were observed, but were of
mild nature and tolerable by the participants who completed
the study
Conclusions: The trial of lamivudine in this group of
inactive HBsAg carrier state cases proved to be safe and
efﬁcacious.
doi:10.1016/j.ijid.2008.05.1093
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Background: HCV infection is very common in intra-
venous drug usres (IDUs) and it has more often progression
in chronic hepatitis. Inspite of that, just small percent of
these patients with chronic hepatitis C (CHC) is treated with
antiviral therapy. Interruption of therapy was common in
IDUs due to low compliance and adverse reactions, usually
psychiatric.
Methods: This is a 5-year retrospective analysis of 37 IDUs
with CHC who were treated in Institute for Infectious and
Tropical Diseases, Clinical Center of Serbia in Belgrade. HCV
RNA and HCV genotype (G) were determinated by PCR. Liver
biopsy was performed in 34 (91,89%) patients. All 37 patients
were treated with pegilated interferon alpha 2a+ Ribavirin
according to standard protocols
Results: There were 37 IDUs with CHC in the age from
17—54 years. They abused heroin iv for 1—21 years. HCV
infection was diagnosed 1—18 years before treatment. All
patients were HBsAg and anti-HIV negative. 18 patients
(48,64%) also consumed alcohol. AST level ranged from
35—248 IU/L. Liver biopsy showed cirrhosis in 5 (14,7%)
patients and ﬁbrosis in 29 (85,3%) patients. Steatosis was
conﬁrmed in 9 (24,32%) patients. Viral load ranged from
